Twak (Cinnamon): Benefits, Evidence, Dosage & Safety

TL;DR

Twak is the Ayurvedic name for cinnamon bark: Cinnamomum verum (Ceylon cinnamon) in the pharmacopoeia, though most trials used cassia. Meta-analyses of RCTs show modest blood-sugar reductions in type 2 diabetes, but NCCIH says evidence is inconclusive. Cassia is high in coumarin, a liver concern; Ceylon has only traces.

(50 words. Sources: API Pt. I Vol. I monograph 71; umbrella meta-analysis, PMID 37316893; NCCIH.)

What it is

Twak is the dried inner bark (devoid of cork and cortex) of the coppiced shoots of Cinnamomum zeylanicum Blume (family Lauraceae), as defined in the Ayurvedic Pharmacopoeia of India, Part I, Volume I, monograph 71 (API Pt. I Vol. I, via text mirror). C. zeylanicum is the older botanical name for what is now accepted as Cinnamomum verum: Ceylon or "true" cinnamon, the species the pharmacopoeia specifies.

Two kinds of cinnamon dominate the market, and the distinction matters: Ceylon cinnamon (C. verum) and cassia cinnamon (Cinnamomum cassia, also called C. aromaticum). The U.S. National Center for Complementary and Integrative Health (NCCIH) notes that the types and parts of cinnamon used in a product differ importantly in chemical composition, and that many products do not clearly state which species they contain (NCCIH). Cassia is what nearly all the diabetes trials actually tested.

Traditional use

Cinnamon has centuries of use as both a spice and a folk or traditional medicine across cultures, including for bronchitis, gastrointestinal complaints, loss of appetite, and diabetes (NCCIH). In Ayurveda, tvak is an aromatic bark used in classical compound formulations: teaching summaries of the tradition list it in preparations such as Sitopaladi churna and Eladi rasayana (college materia-medica summary). These are traditional uses, not clinical proof: the trial evidence is assessed separately below.

What modern research says

Blood sugar in type 2 diabetes

A 2023 umbrella meta-analysis pooled 11 meta-analyses of randomized clinical trials of cinnamon in type 2 diabetes or PCOS. Cinnamon supplementation significantly reduced fasting plasma glucose (weighted mean difference −10.93 mg/dL), insulin, HOMA-IR, and HbA1c: but the HbA1c reduction was small (−0.10%), and the authors positioned cinnamon as an add-on treatment, not a replacement for standard care (umbrella meta-analysis, Diabetology & Metabolic Syndrome).

An earlier Cochrane-style systematic review (10 RCTs, 577 adolescents and adults with type 1 or type 2 diabetes, average dose 2 g/day for about 11 weeks) was more cautious: it could draw no conclusions on fasting glucose and found no statistically significant differences in HbA1c or insulin between cinnamon and control groups: and noted that the trials used primarily Cinnamomum cassia (Cochrane review, PMC).

A narrative review of 11 RCTs (doses 120–6,000 mg/day, 4–16 weeks; seven using cassia, one using C. zeylanicum, three not disclosing the species) found all studies reported some fasting-glucose reduction with only very modest HbA1c decreases: and only four studies reached American Diabetes Association treatment goals. Its conclusion: modest effects as an add-on to medication and lifestyle, with patients advised to continue standard treatment (Journal of the Academy of Nutrition and Dietetics30899-1/abstract)). NCCIH's overall assessment is the most restrained: high-quality clinical evidence is generally lacking, and research does not clearly support using cinnamon for any health condition (NCCIH).

What the evidence does not support (yet)

Claims for cinnamon in cancer, Alzheimer's disease, or cardiovascular protection rest on laboratory and animal work, not human trials. NCCIH notes it is unclear whether cassia cinnamon even works as a mosquito repellent, and there is not enough high-quality evidence to support cinnamon for any specific medical condition (NCCIH).

Ceylon vs cassia: the coumarin issue

This is the most practically important distinction. Cassia cinnamon contains coumarin, the parent compound of the anticoagulant warfarin, at levels that can be high in some products. NCCIH reports interactions between coumarin and the liver, and warns that prolonged use of high-coumarin cassia products could be an issue for sensitive people such as those with liver disease. Ceylon cinnamon contains only trace amounts of coumarin (NCCIH). An umbrella review of cinnamon safety notes that Europe applies a tolerable daily intake for coumarin of 0.1 mg/kg body weight per day, that trial doses stayed within this limit, and that higher chronic intake may lead to liver toxicity (umbrella safety review, PMC).

Dosage

There is no established dose. The diabetes trials used 120 mg to 6 g of oral cinnamon per day (mostly cassia capsules or tablets), with a typical trial averaging about 2 g/day for 4–16 weeks (Cochrane review; JAND review30899-1/abstract)). These are research doses, not recommendations: and because most trials used cassia, their results do not automatically transfer to Ceylon cinnamon or to culinary use. Check the species on any supplement label, since products often do not declare it (NCCIH).

Safety & contraindications

NCCIH's safety summary: cinnamon is likely safe in the amounts commonly used in foods. In larger amounts or with long-term use, it is sometimes associated with gastrointestinal problems or allergic reactions. Never consume cinnamon powder as part of the "cinnamon challenge": serious harm is possible. Topical cinnamon oil or powder may cause skin irritation or contact dermatitis. There are theoretical reasons to suspect interactions with an anticancer medicine and with nicotine; if you take any medication, discuss cinnamon supplements with your clinician (NCCIH).

Specific cautions: people with liver disease should be careful with regular cassia cinnamon because of coumarin (NCCIH). Anyone taking anticoagulant or diabetes medication should talk to their clinician before using cinnamon supplements, since additive blood-sugar or bleeding effects are plausible.

FAQs

Is Ceylon cinnamon better than cassia?

For regular supplemental use, Ceylon (C. verum) has a safety advantage: cassia can contain high levels of coumarin, which is a liver concern with prolonged use, while Ceylon contains only traces (NCCIH). On efficacy, most diabetes trials used cassia, so there is no good head-to-head evidence that one type lowers blood sugar better than the other.

Does cinnamon lower blood sugar?

Probably a little, as an add-on: not as a treatment. Meta-analyses of RCTs show statistically significant but modest reductions in fasting glucose and HbA1c (about −0.10%) in type 2 diabetes (umbrella meta-analysis). NCCIH considers the overall evidence inconclusive and does not support cinnamon for any specific condition (NCCIH).

How much cinnamon is safe per day?

There is no established safe supplemental dose. Europe applies a tolerable daily intake for coumarin of 0.1 mg/kg body weight per day (safety review). Trial doses (up to ~6 g/day of cassia) stayed within coumarin limits over weeks, but long-term safety data are limited. Ceylon cinnamon sidesteps most of the coumarin concern.

Can cinnamon replace my diabetes medication?

No. Reviews consistently frame cinnamon as a possible adjunct to standard hypoglycemic medications and lifestyle measures: and advise patients to continue their prescribed treatment (JAND review30899-1/abstract)).

Is cassia cinnamon bad for the liver?

Cassia can contain substantial coumarin, and NCCIH reports liver interactions with coumarin, flagging prolonged high-coumarin cassia use as a potential issue for sensitive people, especially those with liver disease (NCCIH). Occasional culinary use is not the concern; daily supplemental doses are.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.